NASH drug discovery using human organ-on-chips
2 Aug 2020In this application note, CN BIO discusses how the PhysioMimix™ OOC enables advanced long term in vitro liver cultures and modelling of different stages of NAFLD/ NASH disease in a range of culture conditions. This physiologically relevant assay is designed to help fast-track the investigation of new therapies for this chronic liver disease.
Related products
Request Quote for All Products
The PhysioMimix™ OOC Range of Single and Multi-organ Microphysiological Systems (MPS) by CN Bio
CN BioPhysioMimix™ microphysiological systems generate in vitro microtissues that mimic the structure and function of human tissues and organs. Through the simulation of human biological conditions, they bridge the gap between traditional cell culture and human studies, reliably predicting drug effects to facilitate the accelerated development of safe and efficacious therapeutics.
In vitro NASH Contract Research Services by CN Bio
CN BioCN Bio supports non-alcoholic steatohepatitis (NASH) therapeutic development via fast-track NASH Contract Research Services. NASH Services enable you to gain instant access to CN Bio’s expertise and one of the most advanced human in vitro models available. Submit lead candidates for screening and receive human translatable data for insightful preclinical candidate prioritization, clinical trial design and optimization.